



**ROME**  
**XIV INTERNATIONAL CONGRESS**  
**OF DERMATOLOGY**  
**18-21 JUNE 2025**  
**THE ROADS OF DERMATOLOGY**



**INTERNATIONAL**  
**SOCIETY of**  
**DERMATOLOGY**

## Late Breaking Abstract Submission

LATE-BREAKING ABSTRACT  
SUBMISSION OPENING  
**21 January 2025**

LATE-BREAKING ABSTRACT  
SUBMISSION CLOSING  
**4 February 2025** (GMT +1)

LATE-BREAKING ABSTRACT  
ACCEPTANCE NOTIFICATION  
**Starting from March 2025**

### Guidelines for late breaking abstract submission

The ICD 2025 Scientific Committee recognizes that the results of certain basic or clinical research projects may not be ready by the general abstract submission deadline. Hence, we are offering a call for Late-Breaking Abstract submission for work that is completed after the general abstract submission deadline. We will prioritise novel and interesting abstracts that will enrich the scientific program. The Late-Breaking deadline is not intended to offer a second deadline for regular abstract submission.

Select "Submit now" and follow the steps making sure to carefully complete all sections. If all sections are not completed, your abstract submission will NOT be accepted. The presenting author **MUST REGISTER FOR THE ICD BY 30 APRIL, 2025** before the abstract can officially be accepted for inclusion in the final scientific program.

For additional information, please contact: [icd2025abstract@thetriumph.com](mailto:icd2025abstract@thetriumph.com)

### Rules

1. Authors are required to indicate their preference for either ORAL or POSTER presentation by checking the appropriate box on the submission web page. The ICD Abstracts Committee will make the final decision on the format of the presentation (i.e. oral or poster). A few selected posters will be scheduled for short oral poster presentations.
2. Abstracts cannot be identical to any abstracts which have been previously presented at a major international meeting prior to the ICD 2025 or been published in peer-reviewed journals at the time of abstract submission to ICD

PRESIDENT: **Prof. Giovanni Pellacani**  
SECRETARY GENERAL: **Dr. Nancy Dattola**

[www.icd2025rome.org](http://www.icd2025rome.org)



PROFESSIONAL CONGRESS ORGANIZER

**.Triumph** ITALY



2025. An update of the study is, however, acceptable and authors should indicate this in the abstract title.
- Abstracts will be peer reviewed and ranked according to their scholarly and/or research validity, educational value, clarity of presentation and potential impact on global dermatology.
  - Acceptance of abstracts will be communicated via e-mail to the corresponding author. The Abstracts Committee's decision is final and cannot be appealed.
  - Instructions on the preparation of posters or oral presentation and information about projection facilities will be included with the notification of acceptance.
  - Submission of an abstract indicates that:
    - the author(s) agree to comply with the abstract submission and presentation rules;
    - the author(s) confirm that the presentation is based on scientific and/or clinical methods that are ethical and valid;
    - all authors have contributed to and approved the abstract in its entirety.
  - Accepted abstracts will be published on the ICD 2025 website.
  - Accepted abstracts are official communications of the Congress.
  - The presenting author agrees to register, to attend the Congress, and to present the abstract as scheduled by the ICD. The presenting author must register for the ICD by **30 April 2025**, before the abstract can be accepted for inclusion in the final scientific program.

## Instructions for abstracts preparation

*(Please refer to the Abstract template for specific guidance on formatting)*

- Abstracts must be written and presented in English. Abstracts that are not written in comprehensible English will be rejected and/or returned to the author(s) for revision.
- Abstract must be uploaded in WORD format (.doc; .docx)
- Title, authors' names, authors' affiliation, and presenting author must be provided by filling the online form
  - Title: Use a concise descriptive title that indicates the content of the abstract. Please minimize the use of abbreviations in the title. Commercial trade names for drugs, devices, products, and services should NOT be used in the title.
  - Author: The full name and the full surname for each author must be provided. Do not include degrees or titles.
  - Affiliations: Each author should be listed by department, institution, city, and country.
- The body of the abstract text should not exceed 300 WORDS. The online submission program will automatically not allow submissions that do not fit this requirement. Symbols including superscripts and subscripts can be entered in the online system.



5. The body of the abstract text must be divided into the following subheadings as appropriate. Each sub-heading should be in bold text, begin on a new line, and followed by a colon and space (:). The text for each sub-section should begin immediately after the colon and space (see sample abstract below).

For clinical or investigative studies:

- Introduction:
- Objectives:
- Materials and Method:
- Results:
- Conclusions:

For case reports or case series:

- Background:
- Observations:
- Key message

It is NOT sufficient to simply state that “The results will be discussed.” Only common and standard abbreviations may be used without definition. NO REFERENCES, TABLES, CHARTS OR IMAGES ARE ALLOWED. Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted. Drugs, devices, products, and services should be identified by generic names only within the abstract. The use of commercial drug names, brands and registered trademarks are strictly prohibited. No mention of pharmaceutical company names should be included in the abstract. Data must be given in units (International metric system is preferred) that are generally accepted in scientific publications. All co-authors must agree with the submitted results and conclusions, and consent to being listed as authors. Work involving humans or animals, or material derived from them must have been approved by an institutional ethics committee.

## **Abstract topics**

For reviewing and scheduling purposes, abstracts will be classified into thematic areas. Please indicate on the submission webpage the appropriate topic classifications to which your abstract belongs. Only 1 thematic category may be chosen. The ICD Abstracts Committee will attempt to respect the authors’ choice regarding their self-selection to a specific topic but reserves the right to change the allocation to achieve a well-balanced scientific program.



**ROME**  
**XIV INTERNATIONAL CONGRESS**  
**OF DERMATOLOGY**  
**18-21 JUNE 2025**  
**THE ROADS OF DERMATOLOGY**

## Topics:

1. Acne, Hidradenitis Suppurativa, Rosacea
2. Aesthetic & Cosmetic Dermatology
3. Artificial Intelligence & Skin Imaging
4. Atopic Dermatitis
5. Autoimmune Blistering Diseases
6. Climate Change
7. Contact Dermatitis
8. Cutaneous Adverse Reactions to Drugs
9. Cutaneous Oncology
10. Dermatologic Surgery
11. Dermatopathology
12. Dermoscopy
13. Gender Dermatology
14. Genodermatoses
15. Hair Disorders & Trichoscopy
16. Lasers
17. Medical Dermatology
18. Migrant Health
19. Mucosal Diseases
20. Nail Disorders
21. Novel Therapies
22. Pediatric Dermatology
23. Psychodermatology
24. Photobiology & Phototherapy
25. Physical Therapies (including PDT)
26. Pigmentary Disorders
27. Pruritus & Dysesthesias
28. Psoriasis
29. Sexually Transmitted Infections and HIV
30. Skin Aging: Extrinsic and Intrinsic Factors
31. Skin Infections & Tropical Diseases
32. Skin of Color
33. Teledermatology
34. Urticaria & Angioedema
35. Vasculitis & Vasculopathies
36. Wound Healing & Keloids
37. Miscellaneous



**ROME**  
**XIV INTERNATIONAL CONGRESS**  
**OF DERMATOLOGY**  
**18-21 JUNE 2025**  
**THE ROADS OF DERMATOLOGY**

## Important Deadlines

Online Abstract Submission will be available on the Congress website until **4 February 2025**. Please follow the instructions detailed on the website. Your abstract submission will be acknowledged automatically by email, but this confirmation does not constitute official acceptance for presentation.

## Fax submissions will not be accepted

Submitted abstract can be modified until **4 February 2025** (late breaking abstract submission deadline). Please remove the abstract previously submitted and upload the new document. Authors who wish to withdraw their abstract must send a written request to: [icd2025abstract@thetriumph.com](mailto:icd2025abstract@thetriumph.com)

## Acceptance notification

Authors will be notified by e-mail from March 2025 as to the acceptance status of their submissions. This includes the assignment of session category and presentation format (oral or poster). Detailed instructions regarding requirements and instructions for oral and poster presentations will also be provided at that time. If your abstract is accepted, you must register no later than **30 April 2025**. Unless you register by that date, your abstract will not be included in any ICD publications.